Furthermore, in a prospective, double-blind, randomized, phase II study of refractory angina, autologous G-CSF mobilized CD34+ therapy considerably decreased angina frequency and upgraded exercise endurance, angina onset time, and CCS classification without any adverse cardiovascular side effects (Losordo et al., 2011b). Here, CD34 is linked to angina pectoris.